Clinical Complications, Mortality, and Healthcare Resource Utilization of Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Ontario, Canada: A Retrospective Cohort Study
Patients with SCD with recurrent VOCs had substantially higher rates of complications, mortality, and HCRU than controls, further highlighting the need for novel therapies to reduce VOCs and the associated burden.
Authors
- Irène Wang (ORCID: https://orcid.org/0000-0002-3829-5217)
- Nanxin Li (ORCID: https://orcid.org/0009-0006-4412-0997)
- Carlos Galera Peñaranda
- Jillian Murray
- Kevin H.M. Kuo (ORCID: https://orcid.org/0000-0002-6744-9238)
- Calum S. Neish (ORCID: https://orcid.org/0009-0001-0250-1541)
- Natalie Nightingale (ORCID: https://orcid.org/0000-0001-9988-216X)
- Chuka Udeze
- L. Lilly (ORCID: https://orcid.org/0009-0006-4044-269X)
Institutions
- University of Toronto (CA)
- IQVIA (United Kingdom) (GB)
- Vertex Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1007/s12325-025-03411-4
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Institute for Clinical Evaluative Sciences
- Government of Ontario
- Canadian Institutes of Health Research